Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nowell Solish

Showing results (71-80 of 77) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 77 results.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|February 5, 2021
Preventing and Treating Adverse Events of Injectable Fillers: Evidence-Based Recommendations From the American Society for Dermatologic Surgery Multidisciplinary Task ForceDerek H Jones, Rebecca Fitzgerald, Sue Ellen Cox, et al.
Journal of Cosmetic Dermatology|August 26, 2023
Decades of beauty: Achieving aesthetic goals throughout the lifespanJoel L Cohen, Greg J Goodman, Ada Trindade De Almeida, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|February 6, 2013
Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown linesAlastair Carruthers, Jean Carruthers, William P Coleman, et al.
Plastic and Reconstructive Surgery|April 19, 2024
Efficacy and Safety of OnabotulinumtoxinA for the Treatment of Platysma Prominence: A Randomized Phase 2 Dose-Ranging StudyRod J Rohrich, Vince Bertucci, Steven Dayan, et al.
Aesthetic Surgery Journal|August 3, 2022
PrabotulinumtoxinA vs OnabotulinumtoxinA for the Treatment of Adult Males With Moderate to Severe Glabellar Lines: Post-hoc Analyses of the Phase III Clinical Study DataNowell Solish, Benjamin Ascher, Rui L Avelar, et al.
Aesthetic Surgery Journal|April 6, 2019
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Phase III, Non-Inferiority Study Comparing PrabotulinumtoxinA and OnabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult PatientsBerthold-Josef Rzany, Benjamin Ascher, Rui L Avelar, et al.
JAMA Dermatology|June 17, 2026
Development of a Core Outcome Domain Set for Facial AgingMcKenzie A Dirr, Areeba Ahmed, Daniel I Schlessinger, et al.
Pageof 8

Showing results (71-80 of 77) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 77 results.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|February 5, 2021
Preventing and Treating Adverse Events of Injectable Fillers: Evidence-Based Recommendations From the American Society for Dermatologic Surgery Multidisciplinary Task ForceDerek H Jones, Rebecca Fitzgerald, Sue Ellen Cox, et al.
Journal of Cosmetic Dermatology|August 26, 2023
Decades of beauty: Achieving aesthetic goals throughout the lifespanJoel L Cohen, Greg J Goodman, Ada Trindade De Almeida, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|February 6, 2013
Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown linesAlastair Carruthers, Jean Carruthers, William P Coleman, et al.
Plastic and Reconstructive Surgery|April 19, 2024
Efficacy and Safety of OnabotulinumtoxinA for the Treatment of Platysma Prominence: A Randomized Phase 2 Dose-Ranging StudyRod J Rohrich, Vince Bertucci, Steven Dayan, et al.
Aesthetic Surgery Journal|August 3, 2022
PrabotulinumtoxinA vs OnabotulinumtoxinA for the Treatment of Adult Males With Moderate to Severe Glabellar Lines: Post-hoc Analyses of the Phase III Clinical Study DataNowell Solish, Benjamin Ascher, Rui L Avelar, et al.
Aesthetic Surgery Journal|April 6, 2019
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Phase III, Non-Inferiority Study Comparing PrabotulinumtoxinA and OnabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult PatientsBerthold-Josef Rzany, Benjamin Ascher, Rui L Avelar, et al.
JAMA Dermatology|June 17, 2026
Development of a Core Outcome Domain Set for Facial AgingMcKenzie A Dirr, Areeba Ahmed, Daniel I Schlessinger, et al.
Pageof 8